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The resistance ofcytomegalovirus (CMV) to gancicloviror valgancicloviris a factor in therapeutic failure anddisease progression.
CMV strains resistant to ganciclovir or valganciclovir have been associated with speciﬁc mutations in the UL97 and UL54
genes. Sequencing of both CMV UL97 and UL54 genes was performed to detect the presence of CMV antiviral resistance in six
patients who received ganciclovir (and/orvalganciclovir) and had prolonged detectable CMV DNA in their blood during antiviral
treatment. Sequencing results showed no speciﬁc mutations in either UL97 or UL54 gene of CMV and therefore the CMV strains
in kidney transplant patients who received ganciclovir either prophylactically or therapeutically were from the wild type. Our
results suggest that CMV management and immunosuppression protocols for kidney transplant patients followed in the Organ
Transplant Centre, Kuwait, is very eﬀective in reducing the opportunity of developing CMV antiviral resistance.
1.Introduction
At present, ganciclovir (GCV) and valganciclovir (VGCV)
are the treatment of choice of cytomegalovirus (CMV) in
case of infection in solid organ transplant (SOT) recipients
[1, 2], and their use has led to a decline in the CMV
disease and associated morbidity in SOT recipients [3].
However, with the advent of widespread and prolonged
use of antiviral drugs for CMV prophylaxis and the use of
immunosuppressive drugs, antiviral-resistant CMV mutants
are emerging and are associated with disease progression
[4]. Pre-emptive antiviral therapy in transplant patients, on
the other hand, is thought to be less likely to lead to the
emergence of antiviral drug resistance than is prolonged
prophylaxis. Short course of intravenous GCV prophylaxis
or treatment have not been associated with GCV resistance
in SOT recipient. However, the advent of widespread use of
oral GCV for CMV prophylaxis in SOT recipients has led to
the selection of GCV-resistant CMV mutants [5].
Two CMV gene products are implicated in conferring
resistance to anti-CMV drugs. One of them is the product
of CMV UL97 gene, which is responsible for the ﬁrst
phosphorylation step of GCV, a step necessary for its activity,
and the other is UL54 (pol) gene product, the primary target
of all available antivirals [6]. In this study, our aim was to
investigate the presence of drug resistant mutants among
CMV-infected kidneytransplant patientsgivenGCV(and/or
VGCV) whether prophylactically, or therapeutically.
2.Materialsand Methods
2.1. Patients. A total of 54 CMV PCR positive and D+/R+
kidney transplant patients who received kidney transplants
between the year 2000 and 2005 at the Organ Transplant
Center, Ministry of Health, were involved. Among these
patients, 22 were males and 32 were females with a median
ageof43years. Thesepatientsreceivedantiviral drugsduring
the study period. Blood samples were collected every 2–4
weeks unless patients presented with any signs of illness.
Drug resistance was suspected when CMV load in the
blood failed to decline to undetectable levels despite 2 or
more weeks of antiviral treatment. All patients received2 Advances in Virology
immunosuppressive treatment dependingon theircondition
to reduce the risk of kidney rejection. The therapeutic proto-
col was as follows: (1) induction therapy with IL-2 receptor
blocker, Simulect (Basiliximab), Zenapax (Daclizumab),
and antithymocyte globulin (ATG) for high risk patients
only. (2) Maintenance therapy with Prednisolone, Neoral
(Cyclosporine),CellCept(MycophenolateMofetil),and Pro-
graft (Tacrotimus).
2.2. CMV Treatment. The patients received antiviral drugs
according to the antiviral chemotherapy protocol which
is followed in the Organ Transplant Center; (1) prophy-
laxis therapy with GCV i.v. (5mg/kg/b.i.d) or oral VGC
(900mg/day)for2weeks.(2)Pre-emptivetherapywithGCV
i.v. (5mg/kg/b.i.d) or VGCV (900mg/day) for 2 weeks. (3)
Direct therapy with GCV i.v. (5mg/kg/twice/day) or VGCV
(900mg/twice/day) for 3 weeks followed by either oral GCV
(1g/3×day)or VGCV (900mg/day)until clinical resolution.
2.3. CMV Monitoring. CMV DNA load in EDTA plasma
had been determined prospectively by quantitative real-time
polymerasechainreaction(QPCR)usingprimersandprobes
that targeted the CMV immediate early gene [7].
2.4. Antiviral Resistance Analysis. A 789bp of a high GC
content fragment of UL97 gene was ampliﬁed using the
followingprimerpair[8],CPT1088:(Forward)5 -ACGGTG
CTC ACG GTC TGG AT-3 , CPT1878: (Reverse) 5 -GCC
ATG CTC GCC CAG GAG ACA GG-3 .T h ea m p l i ﬁ e d
region contained the entire known GCV/VGCV-resistance
mutations sites (1260–1994bp), which covers codons 420 to
665. The entire UL54 gene coding for the CMV DNA poly-
merase, which contains all possible known mutations, was
ampliﬁed using a set of three primer pairs that were de-
signed by Primer 3 software for primers design (http://frodo
.wi.mit.edu/primer3/). The primer sequences are listed in
Table 1. After cycle sequencing reactions, sequence anal-
ysis of UL97 and UL54 genes of CMV was performed
using the automated DNA sequencer CEQ 8000 Genetic
Analysis System DNA sequencer (Beckman Coulter, USA)
as described by the manufacturer’s manual. Blast analysis
program (http://www.ncbi.nlm.nih.gov/BLAST)f r o mt h e
National Center for Biotechnology Information (NCBI) was
usedfortheanalysisandalignmentofthesequencesobtained
from the automated sequencer with the sequences of wild
type CMV strains in the Gene bank (GenBank: FJ616285.1)
to identify any of the known mutations in UL-97 or UL54
genes. Table 2 shows a list of known UL54 mutations
conferring GCV resistance in clinical isolates for comparison
[9].
3.Results
3.1. Response of Patients to Antiviral Treatment. The 54 CMV
PCR positive kidney transplant patients were treated with
either GCV or VGCV alone or a combination of the two
drugs for a period ranging between 2-3 weeks and 3 months.
During the treatment period, the patients were monitored
regularly by measuring viral load in their plasma using
the QPCR. Samples from each patient were investigated at
the beginning and after the treatment. Forty-eight patients
responded well to therapy as indicated by the complete
clearance of the virus from the bloodstream at the end of the
therapy. However,6patientsfailed torespond well totherapy
and were further analysed. Table 3 shows in detail the eﬀect
oftheantiviral treatmentontheviralloadintheplasmasam-
plesofthese 6patients. Amongthe 6patients,2 patientswere
treated according to prophylaxis protocol and 4 were treated
accordingtotherapeuticprotocol.Patients1and2hadsevere
CMV disease including pneumonia and graft rejection. In
these patients, the viral load at the start of treatment was
4.1 to 4.2log10 copies/mL, and after treatment, the viral
load was reduced by 2-folds only (2.1–2.3log10 copies/mL).
Patients 3 and 4 had mild symptoms but failed to respond
well to therapy. In these patients, the viral load ranged
4.8–4.9log10 copies/mL at the beginning of treatment and
showed only slight reduction (3.5–3.9log10 copies/mL) after
treatment. Patients 5 and 6, however, had severe form of
CMV disease such as diarrhoea, bleeding, and renal failure
and failed to respond well to therapy as there were no signif-
icant reductions in the viral load after treatment. The viral
load ranged2.8-2.9log10 copies/mLatthebeginning oftreat-
ment and showed a slight reduction (1.7log10 copies/mL)
after treatment.
3.2. CMV Antiviral Resistance in Patients Treated with GCV
and/or VGCV
3.2.1. Clinical Presentation. The above 6 patients had CMV-
related symptoms and were CMV DNA positive by PCR for
more than one-month long period and they did not show
signiﬁcant decreases in viral load despite antiviral treatment.
CMV DNA was isolated from samples of these patients and
were processed for sequence analysis to determine whether
GCV or VGCV treatment had resulted in mutations in the
CMV UL97 or UL54 genes. In patient No. 1 (Figure 1),
t h eﬁ r s tp o s i t i v eC M VD N Aw a so b t a i n e d9 0d a y sa f t e r
transplantation. At this time, the patient had fever, leukope-
nia, and pneumonia. Oral VGCV (900mg/twice/day) was
given for 3 weeks. Although the patient showed considerable
reduction in viral load, he failed to clear the virus totally
and continued to show CMV DNA in the blood. Viral load
was 2.2log10 DNA copies/mL at the end of the treatment.
Patient No. 2 (Figure 1)s u ﬀered from fever, leukopenia,
high creatinine levels, and signs of graft rejection after 90
days posttransplantation. At this time the viral load was
4.9log10 DNA copies/mL. Treatment was started with GCV
given as 5mg/kg/twice/day intravenously for two weeks and
was continued with a maintenance dose of 1g/3×day orally
for three months. During the treatment, the viral load raised
slightly (5.5log10 DNA copies/mL) on day 103 posttrans-
plantation. However, after that the viral load dropped but
the patient failed to clear the virus and remained CMV
DNA positive by day 140 post-transplantation (viral load
of 3.9log10 DNA copies/mL). Patient 3 (Figure 1) received
an induction ATG immunosuppressive therapy becauseAdvances in Virology 3
Table 1: Primer sequences for the ampliﬁcation of UL54 gene.
Primers Region (bp) GC content (%) Size (bp) Codon
NA-1 (Forward)
NA-2 (Reverse) 1794–2394 56% 600 379–579
NA-3 (Forward)
NA-4 (Reverse) 2403–3007 62% 604 582–783
NA-5 (Forward)
NA-6 (Reverse) 3074–3674 59% 600 806–1006
Episode of symptoms Period of GCV treatment
Period of VGCV treatment
Period of prophylaxis CMV DNA analyzed
Patient 1
0
1
2
3
4
5
6
7
8
9
10
Days after transplantation
0
4
7
1
1
1
4
1
8
3
4
6
2
9
0
1
0
2
1
0
4
1
1
0
1
1
9
TX day: 14-12-2000
00000000 0
1.36
2.27
5.2
4.11
Patient 2
90 93 103 133 140
0
1
2
3
4
5
6
7
8
9
10
Days after transplantation
TX day: 10-7-03
4.9 4.56
5.54
3.88 3.98
Patient 3
0
2
4
6
8
10
Days after transplantation
TX day: 28-8-04
0000 0000 000 00
2.8 2.5
1.9
Patient 4
1 37 44 58 64 71 92 169 180 216
0
1
2
3
4
5
6
7
8
9
10
Days after transplantation
TX day: 17-6-04
4.8 4.3
3.5
Patient 5
1 1 52 22 93 94 35 7 1 0 4 1 5 2
0
1
2
3
4
5
6
7
8
9
10
Days after transplantation
TX day: 19-6-04
0 0 0 0 0 0 0
2.8
1.7
Patient 6
11 1 2 5 5 1
0
1
2
3
4
5
6
7
8
9
10
Days after transplantation
TX day: 19-6-04
2.69
2.41
4.15
2.08
1
7
1
1
2
0
2
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2
5
0
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8
8
9
1
1
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1
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Figure 1: Monitoring of the viral load in kidney transplant patients.4 Advances in Virology
he showed HLA mismatch and had cadaver kidney, and
therefore, he was given VGCV prophylaxis (900mg/day)
for two weeks. Despite this, the patient became CMV
positive on day 53 post-transplantation with a viral load
of 2.5log10 DNA copies/mL. The patient suﬀered from
thrombocytopenia, fever, and high ALT, and hence he was
given 5mg/kg/twice/day GCV intravenously for two weeks.
After the treatment period, the symptoms of the patient
were resolved and he became CMV DNA negative in the
blood. The patient had a rebound and showed positive CMV
DNA again at day 113 post transplantation with CMV DNA
load of 2.8log10 DNA copies/mL and was on oral VGCV
(900mg/twice/day)for3months. Despitethelong treatment
period, the patient relapsed at day 211 post-transplantation
and had severe systemic infection with leukopenia, renal
failure, and bleeding. At this time, CMV DNA could be
detected again at relatively lower viral load (1.9log10 DNA
copies/mL). In patient 4 (Figure 1), the ﬁrst CMV DNA
positive sample was detected 169 days after transplantation
and presented with fever and leukopenia. Treatment was
started immediately with GCV (5mg/kg/twice/day) intra-
venouslyfor two weeks. However, after treatment, the patient
failed to clear the virus and remained positive by day 216
post-transplantation and therefore, was positive for CMV
DNA for a total of 124 days. The CMV viral load at
the beginning of treatment was 4.8log10 DNA copies/mL,
which was reduced to 3.5log10 DNA copies/mL by the end
of the treatment. In patient 5 (Figure 1)C M VD N Aw a s
detected at day 104 with a viral load of 2.8log10DNA
copies/mL. At this time the patient presented with fever,
leukopenia and diarrhoea. The patient was treated with
GCV (5mg/kg/twice/day) intravenously for 2 weeks and
then with oral VGCV (900mg/twice/day) for one week.
Following treatment, the patient remained CMV positive
for 95 days with a slight reduction in the viral load by
day 152 (1.7log10 DNA copies/mL). Finally, patient No. 6
(Figure 1) received an induction ATG immunosuppressive
therapy because he showed HLA mismatch, and therefore,
he was given GCV prophylaxis for two weeks. The patient
had symptoms of fever, thrombocytopenia, leukopenia, and
pneumonia on the day of transplantation. CMV DNA was
detected at the day of the transplantation with a viral
load of 2.6log10 DNA copies/mL, and after 11 days post
transplantation with aviral load of2.4log10 DNAcopies/mL.
The patient, however, did not receive treatment immediately,
but was treated on day 25 post-transplantation with GCV
5mg/kg/twice/day intravenously for two weeks. Treatment
withGCVdidnotclearthevirusfromthebloodandtheviral
DNA was still detectable (2.1log10 DNA copies/mL) by day
52 post-transplantation. This patient with severe disease was
not given any other therapeutic such as foscarnet, cidofovir
or leﬂunmide since there is no deﬁned protocol for these
drugs in OTC and because of the side eﬀects of some of
thesedrugs. The patientexpired before thecompletionofthe
follow-up period.
3.3. DNA Alterations in UL97 and UL54 Genes. In order
to investigate the possible presence of CMV drug resistant
Table 2: UL54 mutationsin clinical CMV isolates resistant to GCV
[9].
Region UL54
mutation Amino acid change
IV
N408D
F412C
D413E
Asparagine to aspartic acid
Phenylalanine to cycteine
Aspartic acid to glutamic
acid
δ-region C
L501F Leucine to phenylalanine
L501I Leucine to isoleucine
T503I Threonine to isoleucine
K503R Lysine to arginine
K513E Lysine to glutamic acid
P522A Proline to alanine
T700A Threonine to alanine
II
T700A Threonine to alanine
M715V Valine to methionine
I722V Isoleucine to valine
VI V781I Valine to isoleucine
III
L802M Leucine to methionine
A809V Alanine to valine
G841A Glycine to alanine
Other
S676G Serine to glycine
G678S Glycine to serine
Y751H Tyrosine to histidine
virus, viral DNA from a total of 16 CMV strains from
the six patients described previously were investigated for
mutation by sequencing the UL97 and UL54 genes. These
CMV strains were analysed at the beginning, during, and
after the treatment. Sequencing of CMV UL97 gene segment
of DNA from patient No. 1 did not show any mutations
in the nucleotides as compared with the reference strain.
However, sequencing UL54 gene segments of CMV strain
from the same patients that covered codons 393–576, 593–
765, and 820–991 showed ﬁve silent mutations that did not
result in changes in the amino acid sequence. In patient No.
2, four silent mutations were detected in the gene segment
covered codons 585–775 and 820–990 of UL54 gene that did
not result in changes in the amino acid sequence. However,
no mutations or silent mutation were detected in the UL97
gene. In the case of patient No. 3, no mutations or silent
mutation were detected in the UL97 gene. However, ﬁve
silent mutations were detected in the UL54 gene segments
but these again did not result in changes in amino acid
sequence. It is worth mentioning that sequence analysis of
CMV strain which appeared and collected after ﬁve months
of treatment also did not show any mutations in both UL97
and UL54 that would result in drug resistance. No mutations
orsilentmutationsweredetectedinUL97genesegmentfrom
patient No. 4. However, two silent mutations were detected
in UL54 gene segments which covered codons 593–765.
Moreover, results of UL97 sequence analysis of CMV DNA,
isolated from patient No. 5, did not show any alterations in
the nucleotides. No nucleotide alterations were detected inAdvances in Virology 5
Table 3: Characteristics and outcomes of six patients with clinically suspected drug-resistant CMV.
Patient no. Age/sex Clinical symptoms Drug/regimen Duration of drug
exposure
CMV DNA copy no. (log10/mL)
At the beginning
of therapy After therapy
1 43/F
Fever, leukopenia,
thrombocytopenia,
pneumonia
VGCV/treatment 3 weeks 4.2 2.1
2 47/F Fever, leukopenia,
graft rejection
GCV/treatment and
maintenance
2 weeks treatment
and 3 months
maintenance
4.1 2.3
3 60/M Leukopenia
VGCV/prophylaxis,
GCV &
VGCV/treatment
2 weeks
prophylaxis, 2
weeks + 3 months
treatment
4.9 3.9
4 54/F Fever, leukopenia GCV/treatment 2 weeks 4.8 3.5
5 55/F
Fever, leukopenia,
high creatinene,
diarrhoea
GCV &
VGCV/treatment 3 weeks 2.8 1.7
6 34/F Fever, leukopenia,
renal failure, bleeding
GCV/prophylaxis,
GCV &
VGCV/treatment
2 week
prophylaxis, 3
months treatment
2.9 1.7
UL54gene segment that coveredcodons380–568,while only
a single silent mutation detected in gene segment at codon
721. Finally, in CMV DNAisolated from the blood of patient
N o .6 ,n om u t a t i o n sw e r ed e t e c t e di nU L 9 7g e n es e g m e n t s .
However, three silent mutations were detected in UL54 gene
segment that covered codons 383–572, 593–768, and 815–
995.
4.Discussion
The goal of this study was to investigate the possibility of
the presence of CMV drug resistant mutants after treatment
in kidney transplant. Resistance to GCV is associated with
mutations in either or both of the UL54 and UL97 genes
of CMV. In this study, we have investigated six patients
who received GCV and/or VGCV treatment and who did
not respond well to antiviral therapy and in whom the
viral load did not decrease signiﬁcantly. Sequencing analysis
of DNA of CMV strains collected from these patients at
the beginning and after treatment did not reveal any valid
mutationsin the UL97and UL54 genesthat may conferdrug
resistance. Among the investigated patients, two were given
GCV prophylaxis because they showed HLA-mismatch and
had cadaver kidney. We hypothesized that drug resistance
may have developed in CMV strains collected from these
patients since the possibility of developing drug resistance
after prophylaxis therapy is higher than pre-emptive therapy
or treatment. Nevertheless, we were unable to detect any
mutations in either the UL97 or the UL54 genes of CMV. In
none of the samples taken from the 6 patients who showed
little or no decline in viral load after treatment were we able
to ﬁnd any mutations in either the UL97 or the UL54 gene.
Only silent mutations in UL54 gene were detected. Silent
mutations are alterations in the nucleotide sequence that
do not generally result in alteration in amino acid sequence
of a protein. Boivin et al., have also detected multiple
UL54 mutations of unknown signiﬁcance in clinical strains
isolated from SOT recipients [10]. One possible explanation
of the absence of drug resistance mutants in our patients
is that generally, the incidence of CMV drug resistance in
kidney transplant recipients is known to be rather low when
compared with theincidenceofdrugresistance in othersolid
organ transplant (SOT)andAIDSpatients[11].Inastudyby
Lurain et al., on CMV isolates from SOT patients, it is likely
that the incidence of resistance in lung-transplant recipient
is higher than other recipient and the incidence of resistance
in kidney transplant is rather low [12, 13]. Hantz et al. have
also showed that the proportion of SOT patients in their
cohort study who suﬀered treatment failure in the absence of
antiviral resistance is high [14]. Furthermore, another study
showed that treatment with oral VGCV or intravenous GCV
results in similar and low rates of resistance mutations in
SOT recipients [10]. So, the possibility of detecting drug
resistance in the low number of kidney transplant recipients
studied in this project is very low. Usually, drug resistant
mutants emerge because of the increased selection of these
strains over the wild type as a result of high viral load
associated with exposure to potentially inadequate levels of
the drug for long periods of time. CMV management and
immunosuppressionprotocolsforkidneytransplant patients
followed in the Organ Transplant Centre, Kuwait, are indeed
very eﬀective in reducing the opportunity of developing
CMV antiviral resistance. These protocols are based on
short-term prophylaxis with GCV or VGCV for only high
risk group of patients, and controlled dosage of antiviral
drugs for pre-emptive therapy and treatment of CMV
infection/reactivation and disease in parallel with adjustable
dosage of immunosuppressive therapy. Another factor that6 Advances in Virology
may contribute to the emergence of drug resistance is the
degree of host immune competence; good evidence showed
that rates of CMV-resistant genotypes are higher in more
highly immunosuppressed patients such as bone marrow
recipients [15, 16]. The question is, what are the factors
that may aﬀect the rate of response to antiviral therapy even
in the absence of CMV drug resistance? It was observed in
our study that CMV DNA in patients with high viral loads
tended to persist in the blood for a long period of time
(range 70–124 days). However, CMV DNA in patients with
relatively lower viral loads persisted for a shorter period
(range 46–60 days). Nevertheless, neither group of patients
developed resistance based on gene sequencing analysis that
we have conducted. Our results are in accordance with other
ﬁndings, which showed that patients with a higher CMV
DNA load more often had a slower treatment response
because the time needed to clear DNAemia is related to the
amount of virus [17]. Our results are in agreement with
those of Humar et al., who demonstrated that delays or
failure in clearing the virus are not necessarily related to
CMV drug resistance [18]. Van Der Beek et al., have also
showed that antiviral resistance was observed infrequently in
renal transplant patients who received VGCV and apparently
played a minor role in treatment failure [17]. Finally, one
of the most important features about the epidemiology of
resistance among organ transplant recipients has been the
ﬁnding that CMV drug resistance is seen almost exclusively
in CMV-seronegative recipients of transplants from seropos-
itive donors (D+R−) rather than in seropositive patients, at
leastamong nonlungtransplant recipients [19].In summary,
after the start of therapy, diﬀerent rates of clearance of
CMV are likely to occur due to a combination of diﬀerent
factors including host and virus factors and may not be
related only to the presence of drug resistance mutants. Host
factors, however, may include the presence of pre-existing
immunity to CMV and the degree of exogenous immune
suppression.
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